While statins have both good and bad outcomes in the realm of neuropsychiatry, researchers looked at the possible associations with statins and suicidality, depression, anxiety, and seizures.
Risks for suicidal ideation and depressive symptoms are not different between patients with progressive and relapsing-remitting multiple sclerosis.
Children, adolescents, and young adults have greater risk of self-injurious behavior and suicide ideation if they have a childhood history of epilepsy.
The use of genetic evaluation for suicidal ideation may represent a future application for precision medicine.
The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.
Of all the antidepressant efficacy trials conducted between 1991 and 2013, just 1 explicitly included patients who presented with suicidality.
The use of electrical stimulation devices to treat self-injurious or aggressive behavior has been banned by the Food and Drug Administration.
Between 2000 and 2017, unintentional deaths and suicides related to opioid use have increased substantially, whereas overall deaths from suicide have decreased.
No difference was seen in the risk for serious neuropsychiatric events in patients who received oseltamivir in the 30 days after influenza diagnosis compared with those who did not.
Rates of suicide are significantly higher for individuals diagnosed with a neurological disorder versus the general population.
